ArticleAnnals of surgical oncology2015
Chemoprevention for Breast Cancer.
Article in Annals of surgical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Risk-benefits assessment of tamoxifen or raloxifene as chemoprevention for risk reduction of breast cancer among BRCA1 and BRCA2 carriers: a meta-analysis.Scientific reports · 2025Pooled it
- Risk-Reducing Strategies for Ovarian Cancer inThe oncologist · 2017Pooled it
- The symptom burden of women with a known risk of breast cancer receiving risk reducing medication.Cancer treatment and research communications · 2025Article
- Validation study of risk-reduction activities after personalized breast cancer education tool in the WISDOM study.NPJ breast cancer · 2024Article
- Plasma metabolomics profiles and breast cancer risk.Breast cancer research : BCR · 2024Article
- Article
- Breast Collagen Organization: Variance by Patient Age and Breast Quadrant.Diagnostics (Basel, Switzerland) · 2024Article
- Clinical genetics in breast cancer.Journal of surgical oncology · 2024Review
- Review
- Breast Cancer Screening and Prophylactic Mastectomy for High-Risk Women in Romania.Medicina (Kaunas, Lithuania) · 2024Review
- The Gail Model and Its Use in Preventive Screening: A Comparison of the Corbelli Study.Cureus · 2024Article
- Nature's weapons: Bioactive compounds as anti-cancer agents.AIMS public health · 2024Review
- The Prognostic Quality of Risk Prediction Models to Assess the Individual Breast Cancer Risk in Women: An Overview of Reviews.The breast journal · 2024Review
- Validation Study on Risk-Reduction Activities after Exposure to a Personalized Breast Cancer Risk-Assessment Education Tool in High-Risk Women in the WISDOM Study.Research square · 2023Article
- Phytochemical Targeting of Mitochondria for Breast Cancer Chemoprevention, Therapy, and Sensitization.International journal of molecular sciences · 2022Review
- Urinary Comprehensive Genomic Profiling Correlates Urothelial Carcinoma Mutations with Clinical Risk and Efficacy of Intervention.Journal of clinical medicine · 2022Article
- Use and Applicability of the Gail Model to Calculate Breast Cancer Risk: A Scoping Review.Asian Pacific journal of cancer prevention : APJCP · 2022Article
- Development and pilot of an online, personalized risk assessment tool for a breast cancer precision medicine trial.NPJ breast cancer · 2021Article
- Screening High-Risk Women Veterans for Breast Cancer.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2021Article
- Clinical implementation of an oncology-specific family health history risk assessment tool.Hereditary cancer in clinical practice · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMany women at increased risk for breast cancer could benefit from preventive therapy. Preventive therapy options for breast cancer risk reduction have expanded in the last few years to include both selective receptor modulators (tamoxifen and raloxifene) and aromatase inhibitors (anastrozole and exemestane).
methodsRisk factors that place women at high risk for breast cancer, as well as risk calculation models appropriate for the selection of candidates for preventive therapy, are presented, followed by a review of current guidelines for chemoprevention and results of chemoprevention trials.
resultsThe modified Gail model or Breast Cancer Risk Assessment Tool is the most widely utilized risk assessment calculator to determine eligibility for chemoprevention. Women most likely to benefit from preventive therapy include those at high risk under the age of 50 years and those with atypical hyperplasia. Physician and patient barriers limit widespread acceptance and adherence to preventive therapy.
conclusionsPublished guidelines on chemoprevention for breast cancer have been updated to increase awareness and encourage discussion between patients and their physicians regarding evidence-based studies evaluating the benefits of preventive options for women at increased risk for breast cancer. However, even with increasing awareness and established benefits of preventive therapy, the uptake of chemoprevention has been low, with both physician and patient barriers identified. It is prudent that these barriers be overcome to enable high-risk women with a favorable risk-to-benefit ratio to be offered chemoprevention to reduce their likelihood of developing hormone receptor-positive breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.